Compare TARS & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARS | ERO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2020 | 2021 |
| Metric | TARS | ERO |
|---|---|---|
| Price | $58.46 | $25.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $89.00 | $36.50 |
| AVG Volume (30 Days) | ★ 1.4M | 944.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | $51.94 |
| Revenue Next Year | $30.19 | $2.43 |
| P/E Ratio | ★ N/A | $22.61 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $12.79 |
| 52 Week High | $85.25 | $39.80 |
| Indicator | TARS | ERO |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 48.46 |
| Support Level | $56.05 | $25.42 |
| Resistance Level | $67.14 | $26.77 |
| Average True Range (ATR) | 3.54 | 1.16 |
| MACD | -0.35 | 0.24 |
| Stochastic Oscillator | 23.72 | 65.29 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.